Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)



Status:Active, not recruiting
Conditions:Hospital, Gastrointestinal
Therapuetic Areas:Gastroenterology, Other
Healthy:No
Age Range:18 - 65
Updated:2/28/2019
Start Date:January 2016
End Date:November 2019

Use our guide to learn which trials are right for you!

A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With High, Transsphincteric Cryptoglandular Perianal Fistulas

The investigators propose to study the safety of autologous mesenchymal stromal cell transfer
using a biomatrix (the Gore Fistula Plug) in a Phase I study using a single dose of 20
million cells. 15 adult patients, ages 18 years and older with cryptoglandular fistulas will
be enrolled. Subjects will undergo standard adjuvant therapy including drainage of infection
and placement of a draining seton. Six weeks post placement of the draining seton, the seton
will be replaced with the MSC loaded Gore Fistula Plug; fistula plug as per current clinical
practice. The subjects will be subsequently followed for fistula response and closure for 24
months. This is an autologous product derived from the patient and used only for the same
patient.

The investigators propose to study the safety of autologous mesenchymal stromal cell transfer
using a biomatrix (the Gore® Bio-A® Fistula Plug) in a Phase I study using a single
dose of 20 million cells. 15 adult patients (age > 18 years) with cryptoglandular fistulas
will be enrolled. Subjects will undergo standard adjuvant therapy including drainage of
infection and placement of a draining seton. Six weeks post placement of the draining seton,
the seton will be replaced with the MSC loaded Gore® fistula plug as per current
clinical practice. The subjects will be subsequently followed for fistula response and
closure for 24 months. Study visits are Day 1, Week 2, Week 4, Week 8, Week 12, Week 24, Week
52, and Week 104. This is an autologous product derived from the patient and used only for
the same patient.

Inclusion Criteria

1. Males and females 18-65 years of age.

2. Residents of the United States.

3. Single-tract, transsphincteric anal fistula of cryptoglandular origin. Primary
fistulas (no previous surgical treatment) and those who have failed previous surgical
repairs

4. Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active
metal fragments, claustrophobia

5. Ability to comply with protocol

6. Competent and able to provide written informed consent

Exclusion Criteria

1. Inability to give informed consent.

2. Clinically significant medical conditions within the six months before administration
of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other
conditions that would, in the opinion of the investigators, compromise the safety of
the patient.

3. Specific exclusions; Evidence of hepatitis B, C, or HIV

4. History of cancer including melanoma (with the exception of localized skin cancers)

5. Investigational drug within thirty (30) days of baseline

6. A resident outside the United States

7. Pregnant or breast feeding.

8. History of clinically significant auto-immunity (e.g. Crohn's disease) or any previous
example of fat-directed autoimmunity

9. Previous allergic reaction to a perianal fistula plug.

10. If liposuction is not technically feasible

11. Allergic to local anesthetics

12. Pregnant patients or trying to become pregnant.

13. Non-enterocutaneous tracts (i.e. recto-vaginal, entero-vesicular)

14. Multi-tract, suprasphincteric and extrasphincteric fistula tract extensions

15. Active local infection associated with the fistula
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Phone: 507-284-0495
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials